Detalhe da pesquisa
1.
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
Br J Haematol
; 176(3): 412-420, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27982425
2.
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
Cancer
; 117(10): 2112-9, 2011 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21523723